Resverlogix: The Future of Drug Development

October 4, 2021

Developing safe, epigenetic therapeutics for people suffering from chronic illnesses

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.

The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They're a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups.

For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.

You might also like

Healthcare
Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology

Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology.

Healthcare
Investor Alert - Defence Therapeutics: Developing Immune-related Therapies for Cancer Treatment

Defence Therapeutics is a Canadian biotech company developing immune-related therapies for cancer treatment, including cancer vaccines, antibodies, and drug delivery vehicles.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!